Medinet Co

Medinet Co P/TBV

The Price to Tangible Book Value (P/TBV) of Medinet Co (2370.T) as of Oct 26, 2026 is 2.22. In the previous year, Price to Tangible Book Value (P/TBV) was 1.62 — a change of 37.21% (higher).

P/TBV

2.22

YoY

37.21%

Last updated:

Price to Tangible Book Value (P/TBV) of Medinet Co is 2025 2.22 . Price to Tangible Book Value (P/TBV) of Medinet Co was 2024 1.62 . It decreases by 37.21% higher compared to the previous year.

The Medinet Co P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
2.55 JPY
Jan 1, 2019
3.25 JPY
Jan 1, 2020
1.73 JPY
Jan 1, 2021
1.70 JPY
Jan 1, 2022
1.52 JPY
Jan 1, 2023
1.67 JPY
Jan 1, 2024
1.62 JPY
Jan 1, 2025
2.22 JPY
The Medinet Co P/TBV history
YEARP/TBVYoY
2.22+37.21%
1.62-3.13%
1.67+9.73%
1.52-10.26%
1.70-1.73%
1.73-46.89%
3.25+27.61%
2.55+66.45%
1.53+5.27%
1.45+20.95%
1.20+19.48%
1.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medinet Co Stock analysis

What does Medinet Co do? MEDINET Co., Ltd. generates revenue through its Cell Processing Industry segment, which offers comprehensive support services for immune cell therapy, including clinical use from companies, universities, and research institutes, outsourcing cell processing for clinical trials, and operating cell culture processing facilities. The Cellular Medical Products segment focuses on research and development to obtain approval for manufacturing and marketing cellular medical products. The company serves clients in the healthcare sector, particularly entities involved in immune cell therapy and cellular medical product development. The Cell Processing Industry segment provides outsourcing services for cell processing in clinical trials, catering to companies, universities, and research institutes seeking specialized processing capabilities. The Cellular Medical Products segment develops cellular medical products requiring regulatory approval, targeting manufacturers and marketers in the medical field. Both segments operate under MEDINET's expertise in cell processing and medical product development. MEDINET's business model relies on delivering specialized cell processing services and supporting the regulatory approval process for cellular medical products. The company's clients include organizations engaged in immune cell therapy research and development, as well as those seeking to commercialize cellular medical products. The dual-segment approach ensures comprehensive coverage of the cell processing and medical product development lifecycle. Medinet Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinet Co stock

Price to Tangible Book Value (P/TBV) of Medinet Co is 2.22 in 2025.

Price to Tangible Book Value (P/TBV) of Medinet Co changed from 1.62 to 2.22, representing a 37.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Medinet Co since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Medinet Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Medinet Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Medinet Co